KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 103 filers reported holding KEROS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $63,803 | -92.4% | 1,597 | -90.9% | 0.00% | -92.9% |
Q4 2022 | $840,944 | +32.6% | 17,475 | 0.0% | 0.01% | +27.3% |
Q3 2022 | $634,000 | +31.5% | 17,475 | 0.0% | 0.01% | +37.5% |
Q2 2022 | $482,000 | -92.2% | 17,475 | -84.6% | 0.01% | -91.2% |
Q1 2022 | $6,151,000 | -23.1% | 113,119 | -17.8% | 0.09% | -30.0% |
Q4 2021 | $7,995,000 | +46.8% | 137,636 | 0.0% | 0.13% | +46.1% |
Q3 2021 | $5,445,000 | – | 137,636 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
Atom Investors LP | 49,981 | $3,526,000 | 0.36% |